Boehringer Ingelheim Pharmaceuticals, Inc. Release: BI 201335 Demonstrates Potential toShorten HCV Treatment Duration While Achieving High Sustained Virological Response Rates in Difficult to Treat Patients
SAN FRANCISCO & INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S.A only
“Results from the SILEN-C1 study in difficult to treat virus types are also encouraging and we are keen to see the outcomes of our BI 201335 Phase III studies in 2013.” Boehringer Ingelheim today announced results from two Phase IIb studies evaluating the combination of the company’s next generation protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naïve genotype-1 (GT1) hepatitis C (HCV) patients.1,2 These data were presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) 2011 Liver Meeting in San Francisco, USA.
“Results from the SILEN-C1 study in difficult to treat virus types are also encouraging and we are keen to see the outcomes of our BI 201335 Phase III studies in 2013.” Boehringer Ingelheim today announced results from two Phase IIb studies evaluating the combination of the company’s next generation protease inhibitor, BI 201335, with pegylated interferon (PegIFN) and ribavirin (RBV) in treatment-naïve genotype-1 (GT1) hepatitis C (HCV) patients.1,2 These data were presented in oral sessions at the American Association for the Study of Liver Diseases (AASLD) 2011 Liver Meeting in San Francisco, USA.